CY1108635T1 - Πολυθεραπεια για θεραπευτικη αγωγη ιου ηπατιτιδας β - Google Patents

Πολυθεραπεια για θεραπευτικη αγωγη ιου ηπατιτιδας β

Info

Publication number
CY1108635T1
CY1108635T1 CY20081101433T CY081101433T CY1108635T1 CY 1108635 T1 CY1108635 T1 CY 1108635T1 CY 20081101433 T CY20081101433 T CY 20081101433T CY 081101433 T CY081101433 T CY 081101433T CY 1108635 T1 CY1108635 T1 CY 1108635T1
Authority
CY
Cyprus
Prior art keywords
alternation
administering
combination
directed
virus infection
Prior art date
Application number
CY20081101433T
Other languages
English (en)
Inventor
Philip A Furman
George R Painter
David Barry
Franck Rousseau
Original Assignee
Gilead Sciences, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gilead Sciences, Inc. filed Critical Gilead Sciences, Inc.
Publication of CY1108635T1 publication Critical patent/CY1108635T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Η παρούσα εφεύρεση απευθύνεται σε μέθοδο θεραπείας λοίμωξης ιού ηπατίτιδας Β σε ανθρώπους, η οποία περιλαμβάνει χορήγηση, σε συνδυασμό ή εναλλαγή, συνεργικά αποτελεσματικής ποσότητας παραγόντων που έχουν γνωστή δραστικότητα κατά του ιού ηπατίτιδας Β. Συγκεκριμένα, η εφεύρεση απευθύνεται σε μέθοδο θεραπείας λοίμωξης ιού ηπατίτιδας Β που περιλαμβάνει χορήγηση FTC σε συνδυασμό ή εναλλαγή με πενσικλοβίρη, φαμσικλοβίρη ή Δισ-ΡΟΜ-ΡΜΕΑ. Επιπροσθέτως, η εφεύρεση απευθύνεται σε μέθοδο θεραπείας λοίμωξης ιού ηπατίτιδας Β που περιλαμβάνει χορήγηση L-FMAU σε συνδυασμό ή εναλλαγή με DAPD, πενσικλοβίρη ή Δισ-ΡΟΜ-ΡΜΕΑ. Η εφεύρεση απευθύνεται επιπλέον σε μέθοδο θεραπείας λοίμωξης ιού ηπατίτιδας Β που περιλαμβάνει χορήγηση DAPD σε συνδυασμό ή εναλλαγή με Δισ-ΡΟΜ-ΡΜΕΑ.
CY20081101433T 1998-11-02 2008-12-10 Πολυθεραπεια για θεραπευτικη αγωγη ιου ηπατιτιδας β CY1108635T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10666498P 1998-11-02 1998-11-02
EP03077542A EP1380303B1 (en) 1998-11-02 1999-11-02 Combination therapy to treat hepatitis B virus

Publications (1)

Publication Number Publication Date
CY1108635T1 true CY1108635T1 (el) 2014-04-09

Family

ID=22312611

Family Applications (2)

Application Number Title Priority Date Filing Date
CY20081101433T CY1108635T1 (el) 1998-11-02 2008-12-10 Πολυθεραπεια για θεραπευτικη αγωγη ιου ηπατιτιδας β
CY20101100385T CY1110629T1 (el) 1998-11-02 2010-04-30 Πολυθεραπεια για θεραπευτικη αγωγη ιου ηπατιτιδας β

Family Applications After (1)

Application Number Title Priority Date Filing Date
CY20101100385T CY1110629T1 (el) 1998-11-02 2010-04-30 Πολυθεραπεια για θεραπευτικη αγωγη ιου ηπατιτιδας β

Country Status (16)

Country Link
US (3) US6528515B1 (el)
EP (3) EP1382343B1 (el)
JP (2) JP2002528508A (el)
KR (1) KR100632520B1 (el)
CN (3) CN1173705C (el)
AT (3) ATE457734T1 (el)
AU (1) AU1810600A (el)
CY (2) CY1108635T1 (el)
DE (3) DE69939604D1 (el)
DK (2) DK1382343T3 (el)
ES (3) ES2314157T3 (el)
HK (1) HK1062146A1 (el)
ID (1) ID29471A (el)
IL (3) IL142910A0 (el)
PT (2) PT1380303E (el)
WO (1) WO2000025797A1 (el)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL142910A0 (en) * 1998-11-02 2002-04-21 Triangle Pharmaceuticals Inc Combination therapy to treat hepatitis b virus
ES2345099T3 (es) * 2002-06-19 2010-09-15 Fideline Feromonas tranquilizantes aviarias para disminuir el estres, la ansiedad y la agresividad.
JP4806187B2 (ja) * 2002-07-15 2011-11-02 ギリード・サイエンシズ・インコーポレーテッド Ｂ型肝炎ウイルスの治療のためのｌ−ｆｍａｕとの併用療法
US20040224916A1 (en) * 2003-01-14 2004-11-11 Gilead Sciences, Inc. Compositions and methods for combination antiviral therapy
TWI375560B (en) 2005-06-13 2012-11-01 Gilead Sciences Inc Composition comprising dry granulated emtricitabine and tenofovir df and method for making the same
TWI471145B (zh) 2005-06-13 2015-02-01 Bristol Myers Squibb & Gilead Sciences Llc 單一式藥學劑量型
KR20100127180A (ko) * 2009-05-25 2010-12-03 부광약품 주식회사 클레부딘 및 아데포비어 디피복실을 함유하는 만성 ｂ형 간염 치료용 조성물
CN102917706A (zh) * 2010-05-18 2013-02-06 富光药品株式会社 含有克拉夫定及阿德福韦酯的用于治疗慢性乙型肝炎的组合物
RU2606845C2 (ru) 2010-12-10 2017-01-10 СИГМАФАРМ ЛЭБОРЭТОРИЗ, ЭлЭлСи Высокостабильные композиции перорально активных аналогов нуклеотидов или перорально активных пролекарств аналогов нуклеотидов
WO2016180691A1 (en) * 2015-05-08 2016-11-17 F. Hoffmann-La Roche Ag Novel oxathiolane carboxylic acids and derivatives for the treatment and prophylaxis of virus infection
CN105943547B (zh) * 2016-05-23 2018-01-19 北京慧宝源生物技术股份有限公司 抗hbv的药物组合物及其应用

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US5684153A (en) 1984-08-16 1997-11-04 Beecham Group Plc Process for the preparation of purine derivatives
DE3485225D1 (de) 1983-08-18 1991-12-05 Beecham Group Plc Antivirale guanin-derivate.
US5223263A (en) 1988-07-07 1993-06-29 Vical, Inc. Liponucleotide-containing liposomes
CS264222B1 (en) 1986-07-18 1989-06-13 Holy Antonin N-phosphonylmethoxyalkylderivatives of bases of pytimidine and purine and method of use them
EP0380558A4 (en) 1987-09-22 1991-07-31 The Regents Of The University Of California Liposomal nucleoside analogues for treating aids
US5047407A (en) 1989-02-08 1991-09-10 Iaf Biochem International, Inc. 2-substituted-5-substituted-1,3-oxathiolanes with antiviral properties
GB8904855D0 (en) * 1989-03-03 1989-04-12 Beecham Group Plc Pharmaceutical treatment
US5194654A (en) 1989-11-22 1993-03-16 Vical, Inc. Lipid derivatives of phosphonoacids for liposomal incorporation and method of use
US5411947A (en) 1989-06-28 1995-05-02 Vestar, Inc. Method of converting a drug to an orally available form by covalently bonding a lipid to the drug
US5463092A (en) 1989-11-22 1995-10-31 Vestar, Inc. Lipid derivatives of phosphonacids for liposomal incorporation and method of use
US5700937A (en) 1990-02-01 1997-12-23 Emory University Method for the synthesis, compositions and use of 2'-deoxy-5-fluoro-3'-thiacytidine and related compounds
US5204466A (en) 1990-02-01 1993-04-20 Emory University Method and compositions for the synthesis of bch-189 and related compounds
US6346627B1 (en) 1990-02-01 2002-02-12 Emory University Intermediates in the synthesis of 1,3-oxathiolane nucleoside enantiomers
US6642245B1 (en) 1990-02-01 2003-11-04 Emory University Antiviral activity and resolution of 2-hydroxymethyl-5-(5-fluorocytosin-1-yl)-1,3-oxathiolane
GB9009861D0 (en) 1990-05-02 1990-06-27 Glaxo Group Ltd Chemical compounds
AU7872491A (en) 1990-05-07 1991-11-27 Vical, Inc. Lipid prodrugs of salicylate and nonsteroidal anti-inflammatory drugs
WO1991018914A1 (en) 1990-05-29 1991-12-12 Vical, Inc. Synthesis of glycerol di- and triphosphate derivatives
AU651835B2 (en) 1990-06-13 1994-08-04 Arnold Glazier Phosphorous prodrugs
US5674869A (en) * 1990-07-07 1997-10-07 Beecham Group Plc Pharmaceutical treatment
US5674849A (en) 1990-10-24 1997-10-07 Allelix Biopharmaceuticals Inc. Anti-viral compositions
US5149794A (en) 1990-11-01 1992-09-22 State Of Oregon Covalent lipid-drug conjugates for drug targeting
US5543390A (en) 1990-11-01 1996-08-06 State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education, Acting For And On Behalf Of The Oregon Health Sciences University Covalent microparticle-drug conjugates for biological targeting
US5543389A (en) 1990-11-01 1996-08-06 State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education On Behalf Of The Oregon Health Sciences University, A Non Profit Organization Covalent polar lipid-peptide conjugates for use in salves
US5256641A (en) 1990-11-01 1993-10-26 State Of Oregon Covalent polar lipid-peptide conjugates for immunological targeting
US5925643A (en) 1990-12-05 1999-07-20 Emory University Enantiomerically pure β-D-dioxolane-nucleosides
US5179104A (en) 1990-12-05 1993-01-12 University Of Georgia Research Foundation, Inc. Process for the preparation of enantiomerically pure β-D-(-)-dioxolane-nucleosides
US5444063A (en) 1990-12-05 1995-08-22 Emory University Enantiomerically pure β-D-dioxolane nucleosides with selective anti-Hepatitis B virus activity
IL100502A (en) 1991-01-03 1995-12-08 Iaf Biochem Int PHARMACEUTICAL PREPARATIONS CONTAINING CIS-4-AMINO-1-) 2-HYDROXIMETHIL-1,3-OXETYOLEN-5-IL (-
GB9104740D0 (en) 1991-03-06 1991-04-17 Wellcome Found Antiviral nucleoside combination
WO1992018517A1 (en) 1991-04-17 1992-10-29 Yale University Method of treating or preventing hepatitis b virus
GB9110874D0 (en) 1991-05-20 1991-07-10 Iaf Biochem Int Medicaments
EP0594677A4 (en) 1991-07-12 1997-09-17 Vical Inc Antiviral liponucleosides: treatment of hepatitis b
US5554728A (en) 1991-07-23 1996-09-10 Nexstar Pharmaceuticals, Inc. Lipid conjugates of therapeutic peptides and protease inhibitors
GB9116601D0 (en) 1991-08-01 1991-09-18 Iaf Biochem Int 1,3-oxathiolane nucleoside analogues
US6177435B1 (en) 1992-05-13 2001-01-23 Glaxo Wellcome Inc. Therapeutic combinations
EP0746319A4 (en) 1993-05-12 1997-11-05 Karl Y Hostetler ACYCLOVIR DERIVATIVES FOR TOPICAL USE
US5587362A (en) * 1994-01-28 1996-12-24 Univ. Of Ga Research Foundation L-nucleosides
US5696277A (en) 1994-11-15 1997-12-09 Karl Y. Hostetler Antiviral prodrugs
US5703058A (en) * 1995-01-27 1997-12-30 Emory University Compositions containing 5-fluoro-2',3'-didehydro-2',3'-dideoxycytidine or a mono-, di-, or triphosphate thereof and a second antiviral agent
US5808040A (en) 1995-01-30 1998-09-15 Yale University L-nucleosides incorporated into polymeric structure for stabilization of oligonucleotides
US5869461A (en) 1995-03-16 1999-02-09 Yale University Reducing toxicity of L-nucleosides with D-nucleosides
AU5127098A (en) * 1996-11-29 1998-06-22 Smithkline Beecham Plc Use of a combination of penciclovir and alpha-interferon in the manufacture of a medicament for the treatment of hepatitis
ATE267198T1 (de) * 1997-03-19 2004-06-15 Univ Emory Synthese und anti-hiv und anti-hepatitis virus aktivität von 1,3-oxaselenolan nucleosiden
IL142910A0 (en) * 1998-11-02 2002-04-21 Triangle Pharmaceuticals Inc Combination therapy to treat hepatitis b virus

Also Published As

Publication number Publication date
DE69923338D1 (de) 2005-02-24
IL193148A (en) 2011-09-27
EP1382343A1 (en) 2004-01-21
DK1380303T3 (da) 2008-12-01
HK1062146A1 (en) 2004-10-21
KR20010082282A (ko) 2001-08-29
EP1124562B1 (en) 2005-01-19
JP2011079840A (ja) 2011-04-21
JP2002528508A (ja) 2002-09-03
WO2000025797A1 (en) 2000-05-11
EP1382343B1 (en) 2010-02-17
EP1124562A1 (en) 2001-08-22
ES2338642T3 (es) 2010-05-11
AU1810600A (en) 2000-05-22
ES2314157T3 (es) 2009-03-16
CY1110629T1 (el) 2015-04-29
CN1666742A (zh) 2005-09-14
ATE287268T1 (de) 2005-02-15
DE69939604D1 (de) 2008-10-30
IL142910A (en) 2009-06-15
EP1380303B1 (en) 2008-09-17
DE69923338T2 (de) 2006-04-06
ES2237189T3 (es) 2005-07-16
DE69942042D1 (de) 2010-04-01
CN1891221A (zh) 2007-01-10
US7572800B2 (en) 2009-08-11
IL193148A0 (en) 2009-02-11
KR100632520B1 (ko) 2006-10-09
ATE457734T1 (de) 2010-03-15
US6528515B1 (en) 2003-03-04
ID29471A (id) 2001-08-30
EP1380303A1 (en) 2004-01-14
US20090247487A1 (en) 2009-10-01
PT1382343E (pt) 2010-03-10
PT1380303E (pt) 2008-11-03
CN1173705C (zh) 2004-11-03
DK1382343T3 (da) 2010-04-26
IL142910A0 (en) 2002-04-21
US20030158150A1 (en) 2003-08-21
ATE408410T1 (de) 2008-10-15
CN1329497A (zh) 2002-01-02

Similar Documents

Publication Publication Date Title
CY1110629T1 (el) Πολυθεραπεια για θεραπευτικη αγωγη ιου ηπατιτιδας β
YU96192A (sh) Trombin i postupak za njegovu proizvodnju
DE69233631D1 (de) 1,3-Oxathiolane zur Behandlung von Hepatitis
DE69523350D1 (de) Behandlung von hyperproliferativen Gefässerkrankungen
ATE342728T1 (de) Zubereitung zur behandlung von einer neurologischen erkrankung
FI953592A (fi) 2-(2-amino-1,6-dihydro-6-oksopurin-9-yyli)metoksi-1,3-propaanidiolijohdannainen
DE69205859D1 (de) Verwendung von oberflächenaktiven Mitteln zur Verbesserung des Rückflusses von Venenkathetern.
BR9808221A (pt) Método de tratamento de tumor.
ATE339211T1 (de) L-fmau zur behandlung von hepatitis-delta-virus- infizierung
ATE281173T1 (de) Behandlung einer virusinfektion bei schweinen
ATE255417T1 (de) Verwendung von bradykinin-antagonisten zur behandlung von viruserkrankungen
DE69131058D1 (de) Verwendung einer therapeutischen Zusammensetzung zur Behandlung von Bronchitis
FI945035A (fi) Pintasterilisointi laserkäsittelyn avulla
DE69006187T2 (de) Verwendung von Chinolyl- und Isochinolyloxazol-2-onen zur Herstellung eines Arzneimittels zur Verhinderung der Ansteckungsfähigkeit von mit Glykoproteinen umhüllten Viren.
SE9000658L (sv) Medel foer behandling av soemnapne